Seattle Children's Hospital
seattlechildrens.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
210
Active
54
Phase 3
8
Total enrollment
55,657
Pipeline matrix
Showing 36 of 36 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Exenatide 2 mg [Bydureon] | — | — | — | — | — | 1 | |
| SCRI-CAR22v2 | — | — | — | — | — | 1 | |
| Patient Derived CD19 specific CAR T cells also expressing an EGFRt | — | — | — | — | — | 1 | |
| Phentermine / Topiramate Extended Release Oral Capsule [Qsymia] | — | — | — | — | — | 1 | |
| SC-CAR.GPC3xIL15.21 CAR T cells | — | — | — | — | — | 2 | |
| SC-CAR4BRAIN | — | — | — | — | — | 1 | |
| T-cell Antigen Presenting Cells expressing truncated CD19 | — | — | — | — | — | 1 | |
| SCRI-huCAR19v1 | — | — | — | — | — | 1 | |
| SCRI-huCAR19v2 | — | — | — | — | — | 1 | |
| HER2-specific chimeric antigen receptor (CAR) T cell | — | — | — | — | — | 1 | |
| second generation 4-1BBζ EGFR806-EGFRt | — | — | — | — | — | 1 | |
| second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG | — | — | — | — | — | 1 | |
| SC-DARIC33 | — | — | — | — | — | 1 | |
| SCRI-CAR19v3 | — | — | — | — | — | 1 | |
| second generation 4-1BBζ B7H3-EGFRt-DHFR | — | — | — | — | — | 1 | |
| second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| Autologous CD19 CAR+ EGFTt + T cells | — | — | — | — | — | 1 | |
| Patient-derived CD19- and CD22 specific CAR | — | — | — | — | — | 1 | |
| Fecal Microbiota Transplantation | — | — | — | — | — | 1 | |
| Patient Derived CD171 specific CAR T cells expressing EGFRt | — | — | — | — | — | 1 | |
| SCRI-E2CAR_EGFRtv1 | — | — | — | — | — | 1 | |
| UB_TT170 | — | — | — | — | — | 1 | |
| SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel | — | — | — | — | — | 1 | |
| methotrexate | — | — | — | — | 2 | ||
| Levonorgesterel Intrauterine system | — | — | — | — | — | 1 | |
| Sulfasalazine | — | — | — | — | — | 1 | |
| Leflunomide | — | — | — | — | — | 1 | |
| Pamidronate | — | — | — | — | — | 1 | |
| Zoledronic acid | — | — | — | — | — | 1 | |
| Etanercept | — | — | — | — | — | 1 | |
| Adalimumab | — | — | — | — | — | 1 | |
| Certolizumab | — | — | — | — | — | 1 | |
| Infliximab | — | — | — | — | — | 1 | |
| Golimumab | — | — | — | — | — | 1 | |
| NSAID | — | — | — | — | — | 1 |
Next readouts
- 2015-01-07
- 2021-02-08
- 2021-08-10
- 2021-09-13
- 2023-09
- 2023-09-13
- 2023-11
- 2024-01-17
- 2025-03-12
- 2025-08-08
Top conditions
- Physical Activity11
- Chronic Pain6
- Concussion, Brain6
- Depression6
- Cystic Fibrosis6
- Germ Cell Tumor6
- ADHD5
- Asthma5
Frequently asked questions about Seattle Children's Hospital
- How many clinical trials does Seattle Children's Hospital have on ClinicalTrials.gov?
- Seattle Children's Hospital is listed as the lead sponsor on 210 clinical trials in ClinicalTrials.gov, 54 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Seattle Children's Hospital's trials are in Phase 3?
- 8 of Seattle Children's Hospital's trials are in Phase 3, spread across 36 active drug programs.
- What therapeutic areas does Seattle Children's Hospital focus on?
- Seattle Children's Hospital's most-studied conditions on ClinicalTrials.gov are Physical Activity, Chronic Pain, Concussion, Brain, Depression, Cystic Fibrosis.
- When are Seattle Children's Hospital's next clinical trial readouts?
- Seattle Children's Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia”, expected around 2015-01-07.